Biotech · Private company
EyePoint Pharmaceuticals, Inc.
Track this companyFree. Adds EyePoint Pharmaceuticals, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials174 recruiting or active
Pipeline programs21From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline21
- Aflibercept (2.0 mg)Phase 3 · Diabetic Macular EdemaClinicalTrials.gov · fetched Nov 12, 2026
- Aflibercept (2.0 mg)Phase 3 · Wet Age Related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
- EYP-1901Phase 3 · Wet Age Related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
- EYP-1901Phase 3 · Diabetic Macular EdemaClinicalTrials.gov · fetched Nov 12, 2026
- FAI insertPhase 3 · Non-Infectious UveitisClinicalTrials.gov · fetched Nov 12, 2026
- FAI InsertPhase 3 · UveitisClinicalTrials.gov · fetched Nov 12, 2026
- FAI Insert administered using the Mk I inserterPhase 3 · Non-Infectious UveitisClinicalTrials.gov · fetched Nov 12, 2026
- FAI Insert administered using the Mk II inserterPhase 3 · Non-Infectious UveitisClinicalTrials.gov · fetched Nov 12, 2026
- Sham injectionPhase 3 · Non-Infectious UveitisClinicalTrials.gov · fetched Nov 12, 2026
- Sham InjectorPhase 3 · UveitisClinicalTrials.gov · fetched Nov 12, 2026
- Aflibercept 2mg/0.05mL Inj,OphPhase 2 · Wet Age-related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
- Aflibercept 2Mg/0.05Ml Inj,OphPhase 2 · Diabetic Macular EdemaClinicalTrials.gov · fetched Nov 12, 2026
- AKB-9778Phase 2 · Nonproliferative Diabetic RetinopathyClinicalTrials.gov · fetched Nov 12, 2026
- AKB-9778 4%Phase 2 · Ocular HypertensionClinicalTrials.gov · fetched Nov 12, 2026
- EYP-1901Phase 2 · Nonproliferative Diabetic RetinopathyClinicalTrials.gov · fetched Nov 12, 2026
- Latanoprost ophthalmic solutionPhase 2 · Ocular HypertensionClinicalTrials.gov · fetched Nov 12, 2026
- Razuprotafib Subcutaneous SolutionPhase 2 · COVID-19ClinicalTrials.gov · fetched Nov 12, 2026
- Sham IVTPhase 2 · Nonproliferative Diabetic RetinopathyClinicalTrials.gov · fetched Nov 12, 2026
- DexamethasoneCataractClinicalTrials.gov · fetched Nov 12, 2026
- DEXYCU (dexamethasone intraocular suspension) 9%.CataractClinicalTrials.gov · fetched Nov 12, 2026
- Prednisolone Acetate OphthalmicCataractClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials17
- COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DMEPHASE3 · ACTIVE_NOT_RECRUITING · started Feb 16, 2026ClinicalTrials.gov NCT07449936 · fetched Nov 12, 2026
- CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DMEPHASE3 · ACTIVE_NOT_RECRUITING · started Feb 9, 2026ClinicalTrials.gov NCT07449923 · fetched Nov 12, 2026
- A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56PHASE3 · ACTIVE_NOT_RECRUITING · started Nov 27, 2024ClinicalTrials.gov NCT06683742 · fetched Nov 12, 2026
- A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56PHASE3 · ACTIVE_NOT_RECRUITING · started Oct 22, 2024ClinicalTrials.gov NCT06668064 · fetched Nov 12, 2026
- Study of EYP-1901 in Patients With Diabetic Macular Edema (DME)PHASE2 · COMPLETED · started Jan 15, 2024ClinicalTrials.gov NCT06099184 · fetched Nov 12, 2026
- Study of EYP-1901 in Patients With Nonproliferative Diabetic Retinopathy (NPDR)PHASE2 · COMPLETED · started Sep 28, 2022ClinicalTrials.gov NCT05383209 · fetched Nov 12, 2026
- Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD)PHASE2 · COMPLETED · started Jun 30, 2022ClinicalTrials.gov NCT05381948 · fetched Nov 12, 2026
- Evaluate the Safety of DEXYCU for the Treatment of Inflammation Following Ocular Surgery for Childhood CataractPHASE4 · TERMINATED · started Jan 4, 2022ClinicalTrials.gov NCT05191706 · fetched Nov 12, 2026
- Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal (FAI) InsertPHASE3 · TERMINATED · started Oct 13, 2021ClinicalTrials.gov NCT05070728 · fetched Nov 12, 2026
- First in Human Study to Evaluate the Safety and Tolerability of EYP-1901 in Patients With Wet Age Related Macular Degeneration (wAMD)PHASE1 · COMPLETED · started Jan 20, 2021ClinicalTrials.gov NCT04747197 · fetched Nov 12, 2026
- Evaluation of the Safety and Efficacy of Razuprotafib in Hospitalized Subjects With Coronavirus Disease 2019PHASE2 · TERMINATED · started Oct 21, 2020ClinicalTrials.gov NCT04511650 · fetched Nov 12, 2026
- Study to Assess the Efficacy, Safety and Tolerability of AKB-9778 Ophthalmic Solution as and Adjunct to Latanoprost in Patients With Ocular Hypertension or Open Angle GlaucomaPHASE2 · COMPLETED · started Jun 6, 2020ClinicalTrials.gov NCT04405245 · fetched Nov 12, 2026
- "A Prospective Study of the Efficacy of Intracameral Dexamethasone (Dexycu™) Compared to Standard of Care Treatment for Post-Cataract Surgical Pain and Anterior Chamber Inflammation"PHASE4 · COMPLETED · started Feb 20, 2020ClinicalTrials.gov NCT04781335 · fetched Nov 12, 2026
- DEXYCU (Dexamethasone Intraocular Suspension) 9% Retrospective Study 001COMPLETED · started Nov 13, 2019ClinicalTrials.gov NCT04290676 · fetched Nov 12, 2026
- The TIME-2b Study: A Study of AKB-9778 (Razuprotafib), a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)PHASE2 · COMPLETED · started Jun 9, 2017ClinicalTrials.gov NCT03197870 · fetched Nov 12, 2026
- Utilization and Safety of the Mk II Inserter and the Safety of the FAI Insert in Non-Infectious UveitisPHASE3 · COMPLETED · started Feb 23, 2016ClinicalTrials.gov NCT02748512 · fetched Nov 12, 2026
- Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal InsertPHASE3 · COMPLETED · started Aug 2, 2013ClinicalTrials.gov NCT01694186 · fetched Nov 12, 2026